Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide‐induced lethality
暂无分享,去创建一个
H. Tabuchi | R. Gentz | W. Lesslauer | P. Vassalli | G. Grau | P. Piguet | M. Brockhaus | E. Schlaeger | P. Pointaire | Hunsruedi Loetscher
[1] G. Grau,et al. Prevention of human TNF-induced cutaneous Shwartzmann reaction and acute mortality in mice treated with anti-human TNF monoclonal antibodies. , 1991, Clinical and experimental immunology.
[2] J. Norton,et al. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice , 1991, The Journal of experimental medicine.
[3] G. Spinas,et al. Pretreatment with ibuprofen augments circulating tumor necrosis factor-alpha, interleukin-6, and elastase during acute endotoxinemia. , 1991, The Journal of infectious diseases.
[4] J. Abrams,et al. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. , 1990, Journal of immunology.
[5] Robert C. Thompson,et al. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock , 1990, Nature.
[6] D. Wallach,et al. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. , 1990, The Journal of biological chemistry.
[7] P. Vassalli,et al. Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. , 1990, The American journal of pathology.
[8] P. Zabel,et al. OXPENTIFYLLINE IN ENDOTOXAEMIA , 1989, The Lancet.
[9] J. Dayer,et al. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. , 1989, The Journal of biological chemistry.
[10] D. Wallach,et al. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. , 1989, The Journal of biological chemistry.
[11] K. Karjalainen,et al. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules , 1989, Nature.
[12] E. Nilsson,et al. Isolation and characterization of a tumor necrosis factor binding protein from urine , 1989, European journal of haematology.
[13] I. Olsson,et al. A tumor necrosis factor binding protein is present in human biological fluids , 1988, European journal of haematology.
[14] E. Girardin,et al. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. , 1988, The New England journal of medicine.
[15] A. Cerami,et al. Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.
[16] J. Dayer,et al. A human inhibitor of tumor necrosis factor alpha , 1988, The Journal of experimental medicine.
[17] H. Schreiber,et al. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[18] Kevin J. Tracey,et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.
[19] C. Galanos,et al. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice , 1987, The Journal of experimental medicine.
[20] J. D. Albert,et al. Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.
[21] B. Beutler,et al. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.
[22] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.